Results 211 to 220 of about 288,727 (306)

Longitudinal analysis of usage and public awareness of tyrosine kinase inhibitors for CML. [PDF]

Front Oncol
Schroer AE, Javadi T, Mehta A, Torlak F, McFarland JR, Kumar G, da Silva AL, Benjamin J, Choudhary MM, Sadeghi A, le Coutre P, Blaha MJ, Berning P, Dzaye O.   +13 more
europepmc   +1 more source

Advances in Cancer Immunotherapy for Solid Tumors

Advanced Science, EarlyView.
Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz, Harriet M. Kluger   +1 more
wiley   +1 more source

USP20 governs tyrosine kinase inhibitors resistance through ferroptosis evasion by targeting GPX4 in cancers. [PDF]

Redox Biol
Wang Y, Liu B, Zhuang Y, Zhang Y, Dan W, Ding P, Wei Y, Guo C, Li M, Wang C, Baoerbieke Y, Pei X, Li L, Fan Y.   +13 more
europepmc   +1 more source

PRMT9 Aggravated Dopaminergic Neurodegeneration in Parkinson's Disease Model by Facilitating the Degradation of DUSP26 and Inducing Mitochondrial Dysfunction

Advanced Science, EarlyView.
In the pathological state of PD induced by MPP+, the upregulated PRMT9 in dopaminergic neurons translocates into mitochondrion and interacts with DUSP26 and catalyzes its arginine methylation, leading to the ubiquitin‐proteasomal degradation of DUSP26 mediated by Trim32.
Tengfei Liu, Xiaomeng Song, Xin Guo, Rui Xiao, Ru Sun, Qiuran Ji, Lu Yu, Yiquan Li, Qingyi Fu, Qidi Xue, Lingjun Kong, Lin Chen, Chengjiang Gao, Huiqing Liu   +13 more
wiley   +1 more source

PD-1 inhibitors combined with tyrosine kinase inhibitors for conversion therapy in patients with unresectable hepatocellular carcinoma: a retrospective cohort study. [PDF]

J Gastrointest Oncol
Liu G, Guo C, Li X, Lv Z, Du J, Gong L.
europepmc   +1 more source

Surfaceome Reprogramming of Stemsomes Promotes Lung Cancer Targeting via Potentiated Receptor–Ligand Interactions

Advanced Science, EarlyView.
This study presents a surfaceome‐reprogramming strategy for mutation‐independent lung cancer therapy by repurposing dexamethasone to prime mesenchymal stem cell‐derived nanovesicles. The engineered vesicles leverage multi‐valent interactions mediated by upregulated adhesion proteins, EPHA2, and NOTCH3.
Geunhye Kim, In Ah Kwon, Bo Seop Jeong, Hyo Seon Kim, Joo‐Hwan Park, Sung Jean Park, Sang‐Rae Lee, Youngki Lee, Dongwoo Khang   +8 more
wiley   +1 more source

Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding. [PDF]

J Thromb Thrombolysis
Butel-Simoes LE, Albayati A, Yu J, Quirk T, Sritharan S, French M, Bennetts JD, Ngo DTM, Sverdlov AL.   +8 more
europepmc   +1 more source

Targeting DNGR‐1 with Fangchinoline Elevates Dendritic Cell Antigen Cross‐Presentation‐Mediated Antitumor Immunity in Melanoma

Advanced Science, EarlyView.
Fangchinoline is identified as a small‐molecule DNGR‐1 modulator that enhances dendritic‐cell cross‐presentation of tumor antigens. By engaging DNGR‐1 and activating Syk–Nox2 signaling, it promotes phagosomal ROS, antigen escape, MHC‐I presentation, and CD8+ T‐cell priming, thereby strengthening antitumor immunity and sensitizing tumors to PD‐1 ...
Yuan Liao, Zhenyang Ren, Jing Zhou, He Luo, Yuling Li, Dan Chen, Yuxiao Jiang, Canzhe Li, Mengyi Zheng, Anqi Li, Yao Wang, Yang Zhang, Dingye Wang, Yanjun Jiang, Jiangyong Gu, Biaoyan Du, Yafei Shi, Fang Liu, Jianyong Xiao, Kun Wang   +19 more
wiley   +1 more source

Impact of Tyrosine Kinase Inhibitors on Estimated Glomerular Filtration Rate in Chronic Myeloid Leukemia Patients.

Oncology
Alshurafa A, Benkhadra M, Qasem NM, Babiker AM, Al-Asa'd Y, Haik MY, Yassin MA.   +6 more
europepmc   +1 more source

Next-generation Bruton's tyrosine kinase inhibitors for chronic lymphocytic leukemia-associated membranoproliferative glomerulonephritis: a case report. [PDF]

Ann Hematol
Chen L, Huang Y, Xu J, Huang S, Zhang Q, Hua F, Pan X, Mi JQ.   +7 more
europepmc   +1 more source